Kamada (NASDAQ:KMDA - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $154.06 million for the quarter.
Kamada Stock Down 1.6 %
KMDA traded down $0.11 during trading on Friday, reaching $6.88. 35,837 shares of the stock traded hands, compared to its average volume of 87,052. The stock's 50-day moving average is $6.63 and its 200 day moving average is $6.55. Kamada has a 12 month low of $4.74 and a 12 month high of $9.16. The stock has a market capitalization of $395.46 million, a PE ratio of 24.57, a P/E/G ratio of 0.97 and a beta of 0.94.
Kamada Announces Dividend
The firm also recently announced a -- dividend, which was paid on Monday, April 7th. Investors of record on Monday, March 17th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, March 17th.
Wall Street Analyst Weigh In
A number of research firms have issued reports on KMDA. StockNews.com cut Kamada from a "strong-buy" rating to a "buy" rating in a report on Tuesday, March 25th. HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th. Benchmark started coverage on shares of Kamada in a research report on Friday, March 21st. They set a "buy" rating and a $15.00 price objective on the stock. Finally, Sidoti upgraded Kamada to a "hold" rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.67.
Get Our Latest Stock Analysis on KMDA
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Articles
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
